News|Articles|June 2, 2026

ADA Scientific Sessions 2026 Preview: 6 Trials to Know

View the top 6 trials to watch ahead of a star-studded ADA 2026.

The American Diabetes Association (ADA) 2026 Scientific Sessions are set to begin on Friday, June 5th, in New Orleans, Louisiana. The core of this year’s conference is the myriad GLP-1 therapies that have made substantial strides over recent months. The groundbreaking triple agonist retatrutide will be accompanied by CagriSema, survodutide, and elecoglipron as investigators showcase their efficacy in patients with diabetes and obesity.

Related to this article

Adrian Dan, MD | Image Credit: Summa Health

October 16th, 2026

Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1

A single Revita procedure preserved about 80% of tirzepatide-induced weight loss at six months in the REMAIN-1 pivotal cohort.

October 16th, 2026

Diabetes Dialogue: Twiist AID Data and the New ADA/EASD Type 2 Algorithm

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a major breakthrough with the Twiist insulin pump and the recent ADA/EASD T2D guidelines.

October 15th, 2026

Diabetes Dialogue: Screening, Cell Therapy, and Adjunctive Agents at Breakthrough-T1D

Diana Isaacs, PharmD, and Natalie Bellini, DNP, recap the first-ever Breakthrough T1D Clinical and Research Congress.

October 16th, 2026

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

George Washko, MD, discusses a late-breaking OBERON/TITANIA analysis showing tozorakimab reduces segmental mucus plug scores in COPD.

October 16th, 2026

Elafibranor Lowers ALP in PBC Patients Switching From Obeticholic Acid

Real-world data from ACG 2026 show elafibranor lowered ALP in patients with PBC who switched from obeticholic acid and in those new to second-line therapy.

October 15th, 2026

Q&A: Nemolizumab Sustains Itch, Skin Gains in Early Responders at 3 Years

Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.